What is the primary advantage of automated liquid handling in qPCR-based viral shedding studies?

The principal advantage is a significant increase in data reproducibility by minimizing operator-dependent variability. Automation ensures consistent pipetting volumes, mixing efficiencies, and incubation times across thousands of samples, which directly translates to higher-quality data packages for regulatory submission. This also enables a substantial increase in throughput, reducing analytical timelines.

How does automation mitigate cross-contamination risks in high-sensitivity assays?

Our automated platforms are programmed with stringent anti-contamination protocols. These include the mandatory use of aerosol-resistant filtered pipette tips, optimized liquid classes to prevent splashing, and dedicated on-deck tip wash stations. The controlled, enclosed environment of the liquid handler further reduces the potential for environmental contamination compared to open-bench manual processing.

What sample matrices can be processed using these automated systems?

Our validated automated workflows accommodate a wide range of matrices relevant to viral shedding and biodistribution studies. This includes biofluids such as serum, plasma, urine, and saliva, as well as more complex samples like fecal swabs and tissue homogenates. Each matrix has a specifically optimized extraction protocol to ensure maximum nucleic acid recovery.

How does Franklin Biolabs validate its automated qPCR workflows?

Every automated workflow undergoes rigorous GxP-compliant validation. We perform direct comparisons to established manual methods to demonstrate equivalency or superiority. The validation package assesses key performance characteristics including precision, accuracy, linearity, and the lower and upper limits of quantification (LLOQ/ULOQ) to ensure the method is robust and fit-for-purpose.

Scaling viral shedding and biodistribution studies for AAV and other viral vectors presents a significant logistical and analytical bottleneck. Manual qPCR workflows cannot provide the throughput or consistency required to process the thousands of samples generated from a single large animal study. Franklin Biolabs leverages automated liquid handling systems within our >100,000 sq ft facility to standardize nucleic acid extraction and qPCR plate setup. This approach improves data reproducibility, reduces turnaround times, and strengthens the integrity of the safety data package, directly supporting accelerated development programs targeting an 18-24 month IND timeline.

A comprehensive nonclinical safety assessment requires extensive sampling to accurately characterize the vector’s biodistribution, persistence, and potential for shedding. A typical study can generate several thousand individual samples from various tissues and biofluids, all requiring sensitive molecular analysis.

Processing this sample volume manually introduces significant risks:

• Operator Variability: Minor differences in pipetting technique between analysts can impact nucleic acid yield and qPCR efficiency.

• Increased Error Rate: The repetitive nature of the work increases the likelihood of sample mix-ups or processing errors.

• Logistical Bottlenecks: Manual processing becomes the rate-limiting step, delaying data analysis and program decisions.

Integrating automated liquid handling platforms directly addresses these challenges by systematizing the entire analytical front-end. By replacing manual pipetting with robotic precision, we ensure that every sample is processed under identical conditions. This delivers full sample traceability through LIMS integration and provides a robust, auditable data trail for regulatory review. Our strategic partners in laboratory automation provide the platforms necessary to build these high-capacity workflows.

The accuracy of viral shedding data is contingent on the precision of the underlying analytical method. Research has shown that advanced methods can offer superior precision and robustness over traditional qPCR for the absolute quantification of AAV vectors [PMID: 24328707]. To leverage the power of such precise quantification methods at scale, the pre-analytical workflow must be equally robust. Automation provides the necessary consistency to minimize technical noise, ensuring that the final data reflects true biological signal.

High-quality, high-throughput preclinical data is fundamental for de-risking clinical development. As studies in large animal models have demonstrated, preclinical findings can reveal significant safety and efficacy considerations that directly inform the design of first-in-human trials [PMID: 28806897]. A robust viral shedding data package, generated with the consistency of automation, provides clear, defensible evidence to support the proposed clinical protocol. This level of data integrity has contributed to a 100% IND success rate for programs supported since 2019, noting the Franklin Biolabs brand itself launched in 2024.